Cargando…
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry
BACKGROUND: Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/ritonavir treatment in a large cohort of the latter pat...
Ejemplares similares
-
S292: NIRMATRELVIR/RITONAVIR IN COVID-19 PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES: A REPORT FROMTHE EPICOVIDEHA REGISTRY
por: Salmanton-García, Jon, et al.
Publicado: (2023) -
Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey
por: Cattaneo, Chiara, et al.
Publicado: (2022) -
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
por: Pagano, Livio, et al.
Publicado: (2022) -
Outcome of infection with omicron SARS‐CoV‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
por: Blennow, Ola, et al.
Publicado: (2022) -
Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry
por: Busca, Alessandro, et al.
Publicado: (2023)